Patents by Inventor Walter Mier

Walter Mier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240350680
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: February 13, 2024
    Publication date: October 24, 2024
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Patent number: 11951190
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 11931430
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Publication number: 20230211003
    Abstract: The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.
    Type: Application
    Filed: October 9, 2020
    Publication date: July 6, 2023
    Inventors: STEPHAN URBAN, WALTER MIER
  • Publication number: 20230112012
    Abstract: The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
    Type: Application
    Filed: July 1, 2022
    Publication date: April 13, 2023
    Inventors: Uwe HABERKORN, Anastasia LOKTEV, Thomas LINDNER, Walter MIER, Frederik GIESEL, Clemens KRATOCHWIL
  • Publication number: 20220324898
    Abstract: In particular, the present invention relates to a PSMA binding ligand comprising an oligosaccharide building block which comprises a bond being cleavable by alpha-amylase. Typically, this PSMA binding ligand further comprises a PSMA binding motif Q and a chelator residue A, wherein the PSMA binding motif Q and the chelator residue A are preferably linked via at least one linker LAQ comprising the oligosaccharide building block, the PSMA binding ligand thus preferably having the structure (I) A-LAQ-Q or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 13, 2022
    Inventors: Matthias Eder, klaus Kopka, Martin Schäfer, Ulrike Bauder-Wuest, Uwe Haberkrn, Hans-Christian Kliem, Walter Mier, Thomas Lindner
  • Patent number: 11401304
    Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 2, 2022
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Stephan Urban, Yi Ni, Walter Mier
  • Publication number: 20210393809
    Abstract: The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and -0P03H2, R1 is —CH3 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R2, R3, R4 and R5 are selected from the group consisting of H, —CH2—COOH and —CH2—C(=0)-NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 an
    Type: Application
    Filed: September 27, 2019
    Publication date: December 23, 2021
    Applicants: Universität Heidelbert, Deutsches Krebsforschungszentrum
    Inventors: Uwe HABERKORN, José Carios DOS SANTOS, Walter MIER, Clemens KRATOCHWIL, Ulrike BAUDER-WUEST, Klaus KOPKA, Martin SCHÄFER
  • Patent number: 11202833
    Abstract: The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine-containing protein. Preferred scavenger compounds are said cyclic peptides comprising a specific amino acid motif and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: December 21, 2021
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Sebastian Brings, Thomas H. Fleming, Walter Mier, Peter P. Nawroth
  • Publication number: 20210283279
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: January 7, 2021
    Publication date: September 16, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Publication number: 20210177996
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Inventors: Matthias EDER, Klaus KOPKA, Martin SCHÄFER, Ulrike BAUDER-WÜST, Michael EISENHUT, Walter MIER, Martina BENESOVA
  • Publication number: 20210038749
    Abstract: The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).
    Type: Application
    Filed: February 6, 2019
    Publication date: February 11, 2021
    Inventors: Uwe HABERKORN, Anastasia LOKTEV, Thomas LINDNER, Walter MIER, Frederik GIESEL, Clemens KRATOCHWIL
  • Publication number: 20200283503
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 10, 2020
    Inventors: Alexandra MATZKE-OGI, Véronique ORIAN-ROUSSEAU, Uwe HABERKORN, Thomas LINDNER, Walter MIER
  • Patent number: 10716757
    Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: July 21, 2020
    Assignee: Universität Heidelberg
    Inventors: Gert Fricker, Walter Mier, Frieder Helm, Philipp Uhl, Stephan Urban
  • Patent number: 10703796
    Abstract: The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: July 7, 2020
    Assignees: AMCURE GMBH, RUPRECHT-KARLS-UNIVERSITÄT
    Inventors: Alexandra Matzke-Ogi, Véronique Orian-Rousseau, Uwe Haberkorn, Thomas Lindner, Walter Mier
  • Patent number: 10653796
    Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: May 19, 2020
    Assignee: Universität Heidelberg
    Inventors: Philipp Uhl, Max Sauter, Uwe Haberkorn, Walter Mier, Gert Fricker
  • Publication number: 20200131227
    Abstract: The present invention relates to a polypeptide with tumor binding activity, and its use in the treatment and diagnosis of cancer.
    Type: Application
    Filed: February 27, 2018
    Publication date: April 30, 2020
    Inventors: Uwe HABERKORN, Walter MIER, Max SAUTER, Annette ALTMANN, Christel HEROLD-MENDE, Rolf WARTA, Saskia RÖSCH
  • Publication number: 20200022914
    Abstract: The present invention relates to solid oral dosage forms comprising liposomes, said liposomes comprising conjugates of cell penetrating peptides (CPPs) and a compound, selected from a lipid and a fatty acid, wherein said liposomes are comprised in an enteric-coated capsule or enteric-coated tablet. The present invention further relates to uses of said solid oral dosage forms for the oral delivery of therapeutic and diagnostic agents.
    Type: Application
    Filed: April 3, 2018
    Publication date: January 23, 2020
    Applicant: UNIVERSITÄT HEIDELBERG
    Inventors: Philipp UHL, Max SAUTER, Walter MIER
  • Patent number: 10513539
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: December 24, 2019
    Assignee: Ruprecht-Karls-Universitat Heidelberg
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn